Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M; ASTRAL-5 Investigators. Wyles D, et al. Among authors: kottilil s. Clin Infect Dis. 2017 Jul 1;65(1):6-12. doi: 10.1093/cid/cix260. Clin Infect Dis. 2017. PMID: 28369210 Free PMC article. Clinical Trial.
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
Osinusi A, Rasimas JJ, Bishop R, Proschan M, McLaughlin M, Murphy A, Cortez KJ, Polis MA, Masur H, Rosenstein D, Kottilil S. Osinusi A, et al. Among authors: kottilil s. J Acquir Immune Defic Syndr. 2010 Mar;53(3):357-63. doi: 10.1097/QAI.0b013e3181c7a29d. J Acquir Immune Defic Syndr. 2010. PMID: 20101190 Free PMC article. Clinical Trial.
Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.
Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, Chung TL, Wood BJ, Haagmans BL, Kottilil S, Polis MA. Murphy AA, et al. Among authors: kottilil s. AIDS. 2011 Jun 1;25(9):1179-87. doi: 10.1097/QAD.0b013e3283471d53. AIDS. 2011. PMID: 21593619 Free PMC article. Clinical Trial.
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.
Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E, Subramanian GM, McHutchison JG, Sulkowski MS, Zeuzem S, Nelson DR. Shah SR, et al. Among authors: kottilil s. Clin Gastroenterol Hepatol. 2011 Aug;9(8):688-93. doi: 10.1016/j.cgh.2011.04.029. Epub 2011 May 13. Clin Gastroenterol Hepatol. 2011. PMID: 21640198 Free PMC article. Clinical Trial.
HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.
Sidique N, Kohli A, Shivakumar B, Migueles S, Subramanian GM, Naggie S, Polis MA, Masur H, Kottilil S. Sidique N, et al. Among authors: kottilil s. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e38-40. doi: 10.1097/QAI.0b013e31822d463f. J Acquir Immune Defic Syndr. 2011. PMID: 21921725 Free PMC article. No abstract available.
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S. Naggie S, et al. Among authors: kottilil s. Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2. Hepatology. 2012. PMID: 22331604 Free PMC article. Clinical Trial.
296 results